CHEK2 and breast cancer: Much less information has been reported for other protein-truncating variants and missense variants in CHEK2. Le Calvez-Kelm et al. [15] performed mutation screening in CHEK2 in a population-based series of 1303 women with breast cancer and 1109 unaffected controls.